Cyclophosphamide (generic), Cytoxan
Cyclophosphamide (generic), Cytoxan Newswire (Page 7)

Cyclophosphamide (generic), Cytoxan Newswire (Page 7)

Comprehensive Real-Time News Feed for Cyclophosphamide (generic), Cytoxan. (Page 7)

Results 121 - 140 of 212 in Cyclophosphamide (generic), Cytoxan

  1. Treatment of older patients with mantle-cell lymphoma.Read the original story

    Jan 18, 2015 | CiteULike

    The long-term prognosis for older patients with mantle-cell lymphoma is poor. Chemoimmunotherapy results in low rates of complete remission, and most patients have a relapse.

    Comment?

  2. New test helps guide treatment for bone marrow transplant patients with graft vs. host diseaseRead the original story w/Photo

    Jan 13, 2015 | PhysOrg Weblog

    A new test can guide treatment for patients with graft versus host disease , an often life-threatening complication of bone marrow and stem cell transplants, according to research from the University of Michigan published in Lancet Haematology this month. Patients with fatal blood cancers like leukemia often need bone marrow or stem cell transplants to survive.

    Comment?

  3. A neurologist's guide to safe use of immunomodulatory therapies.Read the original story

    Jan 12, 2015 | CiteULike

    To insert individual citation into a bibliography in a word-processor, select your preferred citation style below and drag-and-drop it into the document. Increased understanding of the pathogenesis of immune-mediated neurologic conditions with concomitant development of new therapeutic agents modulating various aspects of the immune system has resulted in the use of innovative therapies in the treatment of these diseases.

    Comment?

  4. Gut microbiome and anticancer immune response: really hot Sh*tRead the original story

    Jan 12, 2015 | Cell Death and Differentiation

    Cell Death and Differentiation 22, 199–214; doi:10.1038/cdd.2014.56; published online 16 May 2014 12Institut National de la Santé et de la Recherche Médicale, U866, Centre Georges François Leclerc, Dijon, France Correspondence: L Zitvogel, Institut National de la Santé et de la Recherche Médicale, U1015 INSERM, Gustave Roussy, 114 rue Edouard Vaillant, 94805 Villejuif, France. Tel: +33 1 42 11 50 41; Fax: +33 1 42 11 60 94; E-mail: [email protected] The impact of gut microbiota in eliciting innate and adaptive immune responses beneficial for the host in the context of effective therapies against cancer has been highlighted recently.

    Comment?

  5. Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome.Read the original story

    Jan 10, 2015 | CiteULike

    Idiopathic membranous nephropathy is the most common form of nephrotic syndrome in adults. The disease shows a benign or indolent course in the majority of patients, with a rate of spontaneous complete or partial remission of nephrotic syndrome as high as 30% or more.

    Comment?

  6. Activation of the PI3K/Akt pathway by microRNA-22 results in CLL B-cell proliferationRead the original story

    Jan 7, 2015 | Leukemia

    Correspondence: Dr P Oppezzo, Institut Pasteur de Montevideo, Unit of Recombinant Protein, Mataojo 2020, Montevideo 11400, Uruguay. E-mail: [email protected] Received 29 January 2014; Revised 6 May 2014; Accepted 7 May 2014 Accepted article preview online 14 May 2014; Advance online publication 10 June 2014 G1 stages that coexist, in different proportions, with proliferative B cells.

    Comment?

  7. Complement deficiencies limit CD20 monoclonal antibody treatment efficacy in CLLRead the original story

    Jan 7, 2015 | Leukemia

    E-mail: [email protected] or [email protected] Received 27 November 2013; Revised 26 March 2014; Accepted 28 April 2014 Accepted article preview online 2 May 2014; Advance online publication 23 May 2014 Monoclonal antibodies form a central part of chronic lymphocytic leukaemia treatment. We therefore evaluated whether complement defects in CLL patients reduced the induction of complement-dependent cytotoxicity by using anti-CD20 MAbs rituximab and ofatumumab .

    Comment?

  8. Multitarget Therapy for Induction Treatment of Lupus NephritisRead the original story

    Jan 5, 2015 | Annals of Internal Medicine

    The full report is titled "Multitarget Therapy for Induction Treatment of Lupus Nephritis. A Randomized Trial."

    Comment?

  9. New Market Research Report: Emcure Pharmaceuticals Ltd. -...Read the original story

    Dec 26, 2014 | PR-inside.com

    The company develops, manufactures and markets health care products. Its products include Nucron, Xennea, Xennex, Nifirex, Criante, Neuroscience, Global HIV, Pharma, Gennova, Oncocare, and APIs.

    Comment?

  10. A novel fungus concentration-dependent rat model for acute invasive...Read the original story

    Dec 20, 2014 | BioMed Central

    BackgroundAcute invasive fungal rhinosinusitis is a lethal infectious process afflicting immunocompromised individuals. Knowledge about this disease is still limited due to the scarcity of animal models designed to study the pathogenesis of this infection.

    Comment?

  11. Europeans Give Positive Opinion for Velcade Against Mantle Cell LymphomaRead the original story w/Photo

    Dec 19, 2014 | Lymphoma Info

    The Committee for Medicinal Products for Human Use of the European Medicines Agency has given a positive opinion on the use of Bortezomib in mantle cell lymphoma . This new indication covers the use of bortezomib, in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone , for the treatment of adult patients with previously untreated MCL who are unsuitable for hematopoietic stem cell transplantation.

    Comment?

  12. Effectiveness of Drugs to Prevent Hepatitis Among Patients Receiving ChemotherapyRead the original story w/Photo

    Aug 17, 2010 | Science Daily

    Among patients with lymphoma undergoing a certain type of chemotherapy, receiving the antiviral drug entecavir resulted in a lower incidence of hepatitis B virus -related hepatitis and HBV reactivation, compared with the antiviral drug lamivudine, according to a study. Among patients with lymphoma undergoing a certain type of chemotherapy, receiving the antiviral drug entecavir resulted in a lower incidence of hepatitis B virus -related hepatitis and HBV reactivation, compared with the antiviral drug lamivudine, according to a study in the December 17 issue of JAMA .

    Comment?

  13. Herceptin for HER2-positive breast cancer improves long-term survivalRead the original story w/Photo

    Dec 16, 2014 | Medical News Today

    A study that analyzed the long-term safety and effectiveness of trastuzumab - more commonly known as Herceptin - found it significantly improves long-term survival of patients with HER-2 positive breast cancer when combined with chemotherapy. The study, published in the Journal of Clinical Oncology , analyzed data from two independent trials designed to examine overall survival of patients with early-stage HER2-positive breast cancer who received chemotherapy with and without Herceptin.

    Comment?

  14. Study shows superior activity for nab-paclitaxel vs paclitxel in early breast cancerRead the original story w/Photo

    Dec 15, 2014 | Medical News Today

    The German Breast Group said nab-paclitaxel demonstrated significant benefit for patients with early high risk breast cancer when compared to conventional solvent-based paclitaxel. The findings are from the GeparSepto clinical trial sponsored by GBG and conducted together with the German AGO-B study group involving over 1200 patients, which is the largest randomized Phase III study ever completed with nab-paclitaxel and the first one completed in high risk early breast cancer.

    Comment?

  15. Physicians must be the architects of health care changeRead the original story w/Photo

    Dec 13, 2014 | Kevin, M.D.

    Betsy Lehman trusted her life to the American health care system. An award-winning journalist, Lehman was a rising star at the Boston Globe, where she wrote extensively about health care issues.

    Comment?

  16. Metronomic oral cyclophosphamide (MOC) in the salvage therapy of...Read the original story

    Dec 13, 2014 | BioMed Central

    The aim of this multicenter, retrospective study was to evaluate the efficacy and safety of metronomic oral cyclophosphamide in heavily treated, relapsed ovarian cancer patients. oral cyclophosphamide , Baxter, Italy) was administered at the dose of 50 mg daily, continuously.

    Comment?

  17. Merrimack Pharmaceuticals Presents Research on Innovative Pipeline...Read the original story w/Photo

    Dec 12, 2014 | GlobeNewswire

    Merrimack Pharmaceuticals, Inc. today announced data from multiple presentations at the 2014 San Antonio Breast Cancer Symposium in San Antonio, TX. Presentations include preclinical research and clinical data on MM-398, MM-302 and MM-121.

    Comment?

  18. Generic Product NewsRead the original story

    Dec 11, 2014 | Pharmacy Times

    CLINDAMYCIN PALMITATE HYDROCHLORIDE FOR ORAL SOLUTION Marketed by: Amneal Pharmaceuticals Compare to: Cleocin Pediatric Indication: Amneal Pharmaceuticals announced the launch of clindamycin palmitate hydrochloride for oral solution USP , which is available in 75 mg/5 mL reconstituted strength. The Amneal product is an AA-rated therapeutic equivalent to Pharmacia and Upjohn's Cleocin Pediatric.

    Comment?

  19. Phase 3 Results From Demonstrates Superior Activity In High Risk...Read the original story

    Dec 10, 2014 | BioSpace

    Phase 3 Results From German Breast Group Demonstrates Superior Activity In High Risk Early Breast Cancer For Nab-Paclitaxel Vs. Solvent-Based Paclitaxel Oral Presentation of GeparSepto Study Scheduled at the 2014 San Antonio Breast Cancer Symposium, General Session 2, 4:45 PM CT, Wednesday, December 10th-- -- Phase III Results Demonstrate Significant Pathological Complete Response for Nab-Paclitaxel in Neoadjuvant Breast Cancer-- SAN ANTONIO & NEU-ISENBURG, Germany & FRANKFURT, Germany-- --The German Breast Group said nab-paclitaxel demonstrated significant benefit for patients with early high risk breast cancer when compared to conventional solvent-based paclitaxel.

    Comment?

  20. Mononeuritis multiplex as the first presentation of refractory sarcoidosis responsive to etanerceptRead the original story

    Dec 10, 2014 | BioMed Central

    BackgroundSeveral disorders may present with mononeuritis multiplex and the etiological diagnosis can be challenging.Case presentationWe report a 42-year old female who presented with severe lower limb neuropathic pain, asymmetric weakness and sensory impairment and was diagnosed with mononeuritis multiplex. Biopsy showed a granulomatous vasculitic process with eosinophils, scarce granulomata and axonal neuropathy and granulomatosis with poliangiitis was assumed.

    Comment?